AU2004219625B9 - Uses of IL-23 agonists and antagonists; related reagents - Google Patents

Uses of IL-23 agonists and antagonists; related reagents Download PDF

Info

Publication number
AU2004219625B9
AU2004219625B9 AU2004219625A AU2004219625A AU2004219625B9 AU 2004219625 B9 AU2004219625 B9 AU 2004219625B9 AU 2004219625 A AU2004219625 A AU 2004219625A AU 2004219625 A AU2004219625 A AU 2004219625A AU 2004219625 B9 AU2004219625 B9 AU 2004219625B9
Authority
AU
Australia
Prior art keywords
antibody
antagonist
nucleic acid
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004219625A
Other languages
English (en)
Other versions
AU2004219625B2 (en
AU2004219625A1 (en
Inventor
Terrill K. Mcclanahan
Martin Oft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2004219625A1 publication Critical patent/AU2004219625A1/en
Priority to AU2010212372A priority Critical patent/AU2010212372B2/en
Publication of AU2004219625B2 publication Critical patent/AU2004219625B2/en
Application granted granted Critical
Publication of AU2004219625B9 publication Critical patent/AU2004219625B9/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: SCHERING CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2004219625A 2003-03-10 2004-03-09 Uses of IL-23 agonists and antagonists; related reagents Ceased AU2004219625B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010212372A AU2010212372B2 (en) 2003-03-10 2010-08-16 Uses of IL-23 agonists and antagonists; related reagents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
US60/453,672 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010212372A Division AU2010212372B2 (en) 2003-03-10 2010-08-16 Uses of IL-23 agonists and antagonists; related reagents

Publications (3)

Publication Number Publication Date
AU2004219625A1 AU2004219625A1 (en) 2004-09-23
AU2004219625B2 AU2004219625B2 (en) 2010-08-19
AU2004219625B9 true AU2004219625B9 (en) 2010-12-23

Family

ID=32990805

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004219625A Ceased AU2004219625B9 (en) 2003-03-10 2004-03-09 Uses of IL-23 agonists and antagonists; related reagents
AU2010212372A Ceased AU2010212372B2 (en) 2003-03-10 2010-08-16 Uses of IL-23 agonists and antagonists; related reagents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010212372A Ceased AU2010212372B2 (en) 2003-03-10 2010-08-16 Uses of IL-23 agonists and antagonists; related reagents

Country Status (22)

Country Link
US (4) US7282204B2 (enExample)
EP (2) EP2108658B1 (enExample)
JP (4) JP4605798B2 (enExample)
CN (1) CN1759123B (enExample)
AT (1) ATE440864T1 (enExample)
AU (2) AU2004219625B9 (enExample)
BR (1) BRPI0408247A (enExample)
CA (1) CA2518262C (enExample)
CL (1) CL2004000467A1 (enExample)
CY (1) CY1109468T1 (enExample)
DE (1) DE602004022781D1 (enExample)
DK (1) DK1601694T3 (enExample)
ES (1) ES2330220T3 (enExample)
MX (1) MXPA05009717A (enExample)
NO (1) NO20054630L (enExample)
NZ (2) NZ541898A (enExample)
PL (1) PL1601694T3 (enExample)
PT (1) PT1601694E (enExample)
SI (1) SI1601694T1 (enExample)
TW (2) TWI439285B (enExample)
WO (1) WO2004081190A2 (enExample)
ZA (1) ZA200506879B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA05004512A (es) * 2002-10-30 2005-07-26 Genentech Inc Inhibicion de la produccion de il-17.
JP4605798B2 (ja) * 2003-03-10 2011-01-05 シェーリング コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
EP1756138A4 (en) * 2004-03-05 2009-07-01 Archemix Corp HUMAN CYTOKINE FAMILY BINDING APTAMERS AND THEIR USE AS THERAPEUTIC AGENTS OF AUTOIMMUNE DISEASES
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009500021A (ja) * 2005-06-30 2009-01-08 アーケミックス コーポレイション サイトカインのｉｌ−１２ファミリーのポリヌクレオチドおよびポリペプチド
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP1937721B1 (en) 2005-08-25 2010-07-28 Eli Lilly And Company Anti-il-23 antibodies
HUE032131T2 (en) * 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
EP2288621A4 (en) * 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite IL23 RECEPTOR ANTAGONISTS AND THEIR USE
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
CA2740351A1 (en) * 2008-10-20 2010-04-29 Pharmatest Services Ltd. Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
WO2010115786A1 (en) * 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
US10059763B2 (en) 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US11279754B2 (en) 2015-03-11 2022-03-22 Rush University Medical Center Compositions and methods for treating cancer
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
JP2023521870A (ja) * 2020-04-17 2023-05-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ｉｌ－１２及びｉｌ－２３ポリペプチドとその使用
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018051A2 (en) * 1999-09-09 2001-03-15 Schering Corporation Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
WO2001085790A2 (en) * 2000-05-10 2001-11-15 Schering Corporation Mammalian cytokine receptor subunit proteins, related reagents and methods
WO2002029060A2 (en) * 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
JP4605798B2 (ja) * 2003-03-10 2011-01-05 シェーリング コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018051A2 (en) * 1999-09-09 2001-03-15 Schering Corporation Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
WO2001085790A2 (en) * 2000-05-10 2001-11-15 Schering Corporation Mammalian cytokine receptor subunit proteins, related reagents and methods
WO2002029060A2 (en) * 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES

Also Published As

Publication number Publication date
AU2004219625B2 (en) 2010-08-19
DE602004022781D1 (de) 2009-10-08
US20100003251A1 (en) 2010-01-07
US8034341B2 (en) 2011-10-11
US20080057058A1 (en) 2008-03-06
TW201141521A (en) 2011-12-01
ZA200506879B (en) 2006-05-31
ATE440864T1 (de) 2009-09-15
MXPA05009717A (es) 2005-10-18
JP4605798B2 (ja) 2011-01-05
CL2004000467A1 (es) 2005-05-06
AU2004219625A1 (en) 2004-09-23
PL1601694T3 (pl) 2010-02-26
AU2010212372A1 (en) 2010-09-09
CY1109468T1 (el) 2014-08-13
SI1601694T1 (sl) 2010-01-29
US7282204B2 (en) 2007-10-16
TWI439285B (zh) 2014-06-01
BRPI0408247A (pt) 2006-03-01
TWI357336B (en) 2012-02-01
TW200505479A (en) 2005-02-16
CA2518262C (en) 2014-05-06
NO20054630D0 (no) 2005-10-07
PT1601694E (pt) 2009-12-03
JP2014005286A (ja) 2014-01-16
EP2108658B1 (en) 2016-06-08
HK1076477A1 (en) 2006-01-20
AU2010212372B2 (en) 2012-12-20
WO2004081190A2 (en) 2004-09-23
EP1601694B1 (en) 2009-08-26
CA2518262A1 (en) 2004-09-23
CN1759123A (zh) 2006-04-12
ES2330220T3 (es) 2009-12-07
NZ567860A (en) 2009-11-27
CN1759123B (zh) 2011-04-13
JP2006520781A (ja) 2006-09-14
US20120034219A1 (en) 2012-02-09
WO2004081190A3 (en) 2005-02-03
US20040223969A1 (en) 2004-11-11
DK1601694T3 (da) 2009-12-14
EP1601694A2 (en) 2005-12-07
EP2108658A1 (en) 2009-10-14
NO20054630L (no) 2005-10-07
JP2007197453A (ja) 2007-08-09
JP2011032275A (ja) 2011-02-17
NZ541898A (en) 2008-07-31

Similar Documents

Publication Publication Date Title
AU2004219625B9 (en) Uses of IL-23 agonists and antagonists; related reagents
US20100143357A1 (en) Uses of Mammalian Cytokine; Related Reagents
US20110002928A1 (en) Uses of Mammalian Cytokine; Related Reagents
US20050214296A1 (en) Methods of modulating cytokine activity; related reagents
HK1076477B (en) Uses of il-23 antagonists; related reagents
HK1130268A (en) Uses of il-23 agonists and antagonists; related reagents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
SREP Specification republished
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ MERCK SHARP & DOHME CORP. .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired